Oral Anti-Diabetes Drugs vs Insulin for Diabetes
What You Need to Know Before You Apply
What is the purpose of this trial?
This randomized controlled clinical trial will assess whether continuation of home oral antidiabetic agents during hospitalization can be used as a safe and effective alternative to insulin therapy in the management of diabetes in the hospital. The primary outcome of the study is to determine differences in glycemic control as measured by mean daily blood glucose concentration between oral antidiabetic medications and basal bolus therapy in hospitalized patients with type 2 diabetes (T2D).
Will I have to stop taking my current medications?
The trial does not specify if you need to stop your current medications, but it seems to focus on continuing oral antidiabetic drugs during hospitalization. It's best to discuss your specific medications with the trial team.
Are oral antidiabetic drugs generally safe for humans?
Oral antidiabetic drugs (OADs) like metformin and sulfonylureas have a well-established safety record, though metformin can cause stomach discomfort and sulfonylureas may lead to low blood sugar and weight gain. Some newer drugs, like thiazolidinediones, have raised concerns about heart-related issues, but alpha-glucosidase inhibitors are considered safe, despite some tolerability issues.12345
How do oral anti-diabetes drugs differ from insulin for diabetes treatment?
Oral anti-diabetes drugs (OADs) are taken by mouth and work in various ways, such as reducing sugar production in the liver or increasing insulin sensitivity, while insulin is injected and directly provides the hormone needed to regulate blood sugar. OADs can be used alone or in combination with other drugs, but many patients eventually need insulin to maintain blood sugar control.36789
What data supports the effectiveness of oral anti-diabetes drugs for diabetes?
Who Is on the Research Team?
Maya Fayfman, MD
Principal Investigator
Emory University
Are You a Good Fit for This Trial?
This trial is for adults aged 18-80 with type 2 diabetes, admitted to general medicine and surgery services, not critically ill or pregnant. Participants must have a blood glucose under 250 mg/dl, HbA1c below 10%, be on oral anti-diabetes drugs (OADs), and have functioning kidneys. Those with type 1 diabetes, severe COVID-19, or on steroids can't join.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants continue their home oral antidiabetic agents or switch to basal bolus insulin therapy during hospitalization
Follow-up
Participants are monitored for safety and effectiveness after treatment, including hospital complications and re-admissions
What Are the Treatments Tested in This Trial?
Interventions
- Oral Anti-diabetes Drugs
Oral Anti-diabetes Drugs is already approved in European Union, United States, Canada, Japan, China, Switzerland for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Emory University
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator